Key Takeaways for IDEXX Laboratories Stock as of August 2026
- Broad-Based Beat: IDEXX Laboratories posted Q2 revenue of $1,216.59M against Street estimates of $1,200.36M, a 1.35% beat, while adjusted EPS of $4.27 topped the $3.93 estimate by 8.54%.
- Guidance Raised Again: Management lifted full-year EPS guidance to $14.69-$14.94 per share and revenue to $4,700M-$4,745M, with organic CAG Diagnostics recurring revenue growth now guided to ~9.5%-10.7%.
- Free Cash Flow Miss: FCF of $322.52M fell 31.34% short of the $469.75M Street estimate, even as CFO grew 86.90% YoY, a rare soft spot in an otherwise clean quarter.
- CEO on inVue Dx: New CEO Michael Erickson called the diagnostic instrument’s rollout “one of the most successful product launches” the company has ever had, with 9,000 units placed since launch.
IDEXX Laboratories just beat on every major line except free cash flow. See the full breakdown and analyze IDXX stock on TIKR for free →
Record inVue Dx Momentum Pushes IDEXX Stock Past Its Own Raised Guide
IDEXX Laboratories (IDXX) delivered a Q2 2026 quarter that beat its own recently raised bar, with revenue of $1,216.59 million topping Street estimates of $1,200.36 million and climbing 9.66% year over year. Adjusted EPS came in at $4.27, an 8.54% beat versus the $3.93 estimate, and CFO Andrew Emerson described the quarter as one where “IDEXX delivered excellent financial results, building on strong execution and expansion of IDEXX innovations in our Companion Animal business.” That expansion showed up directly in the margin line: EBIT margins hit 34.98%, up 103 basis points versus estimates and 136 basis points year over year.
The engine behind that margin gain was CAG Diagnostics, the company’s core veterinary diagnostics segment, where recurring revenue grew 10.3% organically. That growth came even as U.S. same-store clinical visits declined 1.3% in the quarter, a gap Emerson called an “IDEXX U.S. CAG Diagnostics recurring revenue growth premium to U.S. clinical visits of approximately 1,100 basis points.” Instrument placements told a similar story. IDEXX placed 5,265 premium instruments in the quarter, including 1,602 units of its inVue Dx cytology analyzer, bringing first-half placements to 2,700 and total placements since launch to 9,000.
CEO Michael Erickson leaned into that number on the Q2 earnings call: “the launch and progression of inVue Dx has been just outstanding, really one of the most successful product rollouts that we’ve had at the company.” He pointed to consumable revenue per instrument holding “comfortably within the range” of $3,500 to $5,500, with a new fine needle aspirate application entering broader rollout ahead of full availability by year-end.
Not every line cooperated. Free cash flow of $322.52 million missed the $469.75 million estimate by 31.34%, even though cash flow from operations jumped 86.90% year over year to $347.16 million. The gap traces to capital spending, which came in at $24.65 million against a guided $48.85 million, timing that likely shifts rather than erases the shortfall. Management still raised full-year EPS guidance to $14.69-$14.94 and revenue guidance to $4,700-$4,745 million, betting that recurring diagnostics growth keeps outrunning the visit declines dragging on the broader veterinary sector.
IDEXX raised guidance for the second straight quarter while inVue Dx placements hit 9,000 units. See what that means for the stock’s target price and analyze IDXX stock on TIKR for free →
TIKR Values IDXX Stock at $1,043, Pricing In Sustained Diagnostics Growth Through 2030
TIKR’s mid-case model values IDEXX Laboratories at $1,043 by realization, implying a 78% total return from the current price of $585, or 14% annualized over 4.4 years.
That annualized return sits well above what a mature, large-cap diagnostics name typically offers investors, a return profile that assumes IDEXX stock keeps compounding earnings growth rather than simply holding its current multiple. The model’s mid-case scenario pairs 9.6% revenue growth with a 27.3% net income margin, translating into 12.9% EPS growth even as the model bakes in a modest 2.7% annual contraction in the stock’s price-to-earnings ratio.
The target lines up with what Q2 already showed: CAG Diagnostics recurring revenue growing north of 10% and margins expanding on the back of that mix, the exact combination the model needs to sustain double-digit earnings growth through 2030. IDEXX’s 9,000 inVue Dx placements and expanding Cancer Dx panel give the recurring revenue engine more room to run even as clinical visit growth stays pressured.
TIKR’s model points to $1,043 for IDXX stock, a 78% return from current levels. Dig into the full model and analyze IDXX stock on TIKR for free →
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX Laboratories, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDXX stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
